• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Drug Discovery | Pharma |News, Analysis, Insights - HIT Consultant

 

Absci and MSK Collaborate on Generative AI Drug Discovery

by Fred Pennic 08/12/2024 Leave a Comment

Absci and MSK Collaborate on Generative AI Drug Discovery

What You Should Know:  - Absci Corporation, a leader in generative AI drug creation, today announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK) to develop up to six novel cancer therapeutics.  - By combining Absci’s AI platform with MSK’s renowned cancer research expertise, the partnership aims to accelerate the discovery and development of new treatments for this devastating disease. Absci's Integrated Drug Creation Platform Absci's Integrated
Read More

Genomics plc Expands Drug Discovery Collaboration with Vertex

by Syed Hamza Sohail 07/16/2024 Leave a Comment

Genomics plc Expands Drug Discovery Collaboration with Vertex

What You Should Know: -Genomics plc (Genomics), a healthcare company transforming health through the power of genomics today announced a three-year extension of the company’s collaboration with Vertex Pharmaceuticals Incorporated (Vertex) (Nasdaq: VRTX) to use human genetics and machine learning to improve the discovery and development of new precision medicines. -The partnership, which began in 2018, was previously extended in 2021. The collaboration will now run until 2026. Vertex and
Read More

Athos Therapeutics Taps Vultr Cloud GPU to Power AI Drug Discovery Engine

by Syed Hamza Sohail 06/19/2024 Leave a Comment

Athos Therapeutics Taps Vultr Cloud GPU to Power AI Drug Discovery Engine

What You Should Know: -              Vultr, the world’s largest, privately-held cloud computing platform, today announced that Athos Therapeutics, Inc. (“Athos”), a clinical-stage biotechnology company, has chosen Vultr Cloud GPU to run its AI model training, tuning, and inference. -              Powered by NVIDIA HGX H100 systems and running on Dell
Read More

Helix Launches Clinico-Genomic Datasets to Accelerate Precision Medicine Drug Discovery

by Fred Pennic 06/07/2024 Leave a Comment

Helix Launches Clinico-Genomic Datasets to Accelerate Precision Medicine Drug Discovery

What You Should Know:  - Helix, a leader in population genomics, is launching new datasets designed to empower life science companies in developing precision medicine therapies.  - These comprehensive datasets, built through collaborations with various health systems, provide researchers with a rich resource for drug discovery and development across multiple disease areas. Unveiling the Power of Clinico-Genomic Data The datasets offer a unique combination of longitudinal
Read More

Weave Bio Launches for AI-Powered Drug Development, Secures $10M

by Fred Pennic 05/30/2024 Leave a Comment

Weave Bio Launches for AI-Powered Drug Development, Secures $10M

What You Should Know:  - Weave Bio, an AI-native life sciences platform company, announced today the public release of its flagship offering, AutoIND, and $10 million in seed funding co-led by Innovation Endeavors and Magnetic Ventures.  - AutoIND marks a significant advancement in drug development by automating and accelerating the preparation, writing, and review process for Investigational New Drug (IND) applications. Automating the IND Process: A Game-Changer for Drug
Read More

Sanofi, Formation Bio, OpenAI Partner on AI-Powered Drug Discovery

by Fred Pennic 05/21/2024 Leave a Comment

Sanofi, Formation Bio, OpenAI Partner on AI-Powered Drug Discovery

What You Should Know:  - Sanofi, a global pharmaceutical leader, Formation Bio, an AI-powered drug developer, and OpenAI, a leading research and development company in artificial intelligence, have announced a groundbreaking collaboration.  The first-of-its-kind partnership in the pharma and life sciences industries aims to leverage AI to accelerate drug development and bring new medicines to patients faster. - Sanofi, Formation Bio, and OpenAI believe this collaboration will be
Read More

Accenture Backs Turbine’s AI-Powered Platform to Accelerate Drug Discovery

by Fred Pennic 05/16/2024 Leave a Comment

Accenture Backs Turbine's AI-Powered Platform to Accelerate Drug Discovery

What You Should Know:  - Accenture Ventures, the venture capital arm of Accenture, has announced a strategic investment in Turbine, a company pioneering the use of predictive cell simulations for drug development.  - The investment aims to empower Turbine in extending its innovative technology to global biopharmaceutical companies seeking to unlock hidden biological insights and accelerate crucial drug development processes. Optimizing Drug Discovery with Simulated
Read More

Every Cure and BioPhy Partner to Repurpose Existing Drugs Faster with AI

by Jasmine Pennic 05/03/2024 Leave a Comment

Every Cure and BioPhy Partner to Repurpose Existing Drugs Faster with AI

What You Should Know: - BioPhy, an AI drug development company, and Every Cure, a non-profit dedicated to unlocking the potential of existing drugs for new uses, today announced a strategic partnership to revolutionize drug repurposing through artificial intelligence (AI). - The partnership follows Every Cure's recent funding from the Advanced Research Projects Agency for Health (ARPA-H). A successful pilot using AI led to the identification of potential treatments for diseases like sickle
Read More

Deciphex & Novartis Partner on AI-Powered Pathology for Drug Discovery

by Fred Pennic 04/23/2024 Leave a Comment

Deciphex & Novartis Partner on AI-Powered Pathology for Drug Discovery

What You Should Know:  - Deciphex, a leading digital pathology company based in Dublin, Ireland, has announced a collaborative effort with Novartis, a prominent multinational pharmaceutical corporation.  - The strategic partnership focuses on developing innovative artificial intelligence (AI) solutions aimed at revolutionizing preclinical pathology assessments within the drug discovery and development process. Optimizing Preclinical Pathology with AI The collaboration
Read More

NVIDIA Healthcare Launches Generative AI Microservices for Drug Discovery

by Syed Hamza Sohail 03/19/2024 Leave a Comment

What You Should Know: NVIDIA today launched more than two dozen new microservices that allow healthcare enterprises worldwide to take advantage of the latest advances in generative AI from anywhere and on any cloud.The new suite of NVIDIA healthcare microservices includes optimized NVIDIA NIM AI models and workflows with industry-standard APIs, or application programming interfaces, to serve as building blocks for creating and deploying cloud-native applications. They offer advanced
Read More

  • Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to page 5
  • Interim pages omitted …
  • Go to page 13
  • Next Page

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Moving Beyond EHRs: What Lies Ahead for Healthcare Digitization?

AI Agents vs. Chatbots: Understanding Agentic AI’s Role in Healthcare

AI Breakthrough Reveals 2025 AI Breakthrough Award Winners

AI Breakthrough Reveals 2025 AI Breakthrough Award Winners

Healthcare's Big Blind Spot: The Measurement Crisis in Inpatient Psychiatry

Healthcare’s Big Blind Spot: The Measurement Crisis in Inpatient Psychiatry

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |